Neurokinin antagonists and their potential role in treating depression and other stress disorders

Bibliography

• HOLMES A, HEILIG M, RUPNIAK NM, STECKLER T, GRIEBEL G: Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharm. ScL (2003) 24:580–588.
   PubMed Web of Science ®Google Scholar
• •Review of neuropeptides in CNS disorders.
   Google Scholar
• DATAR P, SRIVASTAVA S, COUTINHO E, GOVIL G: Substance P: structure, function, and therapeutics. Curi: Top. Med. Chem. (2004) 4:75–103.
   PubMed Web of Science ®Google Scholar
• GIARDINA GA, GAGLIARDI S, MARTINELLI M: Antagonists at the neurokinin receptors - recent patent literature. IDrugs (2003) 6:758–772.
   PubMed Web of Science ®Google Scholar
• •Detailed review of neurokinin antagonist progress.
   Google Scholar
• JOHANSSON A: Recent developments in the medicinal chemistry of NK2 receptor antagonists. Curi: Top. Med. Chem. (2003) 3:1436–1445.
   Google Scholar
• HUMPHREY JM: Medicinal chemistry of selective neurokinin-1 antagonists. Carr: Top. Med. Chem. (2003) 3:1423–1435.
   Google Scholar
• KEHNE JH, MAYNARD GD, DE LOMBAERT S, KRAUSE JE: Neuropeptide receptor antagonists for CNS disorders. Ann. Rep. Med. Chem. (2003) 38:11–20.
   Google Scholar
• PACHER P, KECSKEMETI V: Trends inthe development of new antidepressants. Is there a light at the end of the tunnel? Carr: Med. Chem. (2004) 11:925–943.
   Google Scholar
• RUPNIAK NM: Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Can: Opin. Invest. Drugs (2002) 3:257–261.
   Google Scholar
• ADELL A: Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Current Drug Targets: CNS & Neurological Disorders (2004) 3:113–121.
   PubMedGoogle Scholar
• TOONEY PA, AU GG, CHAHL LA: Tachyldnin NK1 and NK3 receptors in the prefrontal cortex of the human brain. Clin. Exp. Pharmacol Physiol (2000) 27:947–949.
   PubMedGoogle Scholar
• MILEUSNIC D, MAGNUSON DJ, HEJNA MJ et al.: Age and species-dependent differences in the neurokinin B system in rat and human brain. Neurobiol Aging (1999) 20:19–35.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640–1645.
   PubMed Web of Science ®Google Scholar
• BERGSTROM M, HARGREAVES RJ, BURNS HD et al.: Human positron emission tomography studies of brain neurokinin-1 receptor occupancy by aprepitant. Biol. Psych. (2004) 55:1007–1012.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, WINOKUR A, KELSEY Jet al.: Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology (2004) 29:385–392.
   Google Scholar
• HOFFMANN T, BALLARD T, BOS M et al.: Annual meeting on frontiers in medicinal chemistry, Erlangen, Germany, 15–17 March (2004).
   Google Scholar
• STEVENSON GI, HUSCROFT I, MACLEOD AM et al.: 4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity.i. Med. Chem. (1998) 41:4623–4635.
   Google Scholar
• OKANO S, IKEURA Y, INATOMI N: Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. Pharmacol Exp. TheL (2002) 300:925–931.
   PubMed Web of Science ®Google Scholar
• NATSUGARI H, IKEURA Y, KAMO I et al.: Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK1 receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions.' Merl Chem. (1999) 42:3982–3993.
   PubMed Web of Science ®Google Scholar
• ISHICHI Y, IKEURA Y, NATSUGARI H: Amide-based atropisomers in tachykinin NK1-receptor antagonists: synthesis and antagonistic activity of axially chiral N-benzykarboxamide derivatives of 2,3,4,5-tetrahydro-6H-pyrido[2,3-b] [1,5]oxazocin-6-one. 7etr. (2004) 60:4481–4490.
   Google Scholar
• POULSEN A, BJORNHOLM B, GUNDERTOFTE K, POGOZHEVA ID, LILJEFORS T: Pharmacophore and receptor models for neurokinin receptors. " Comp. Aided Ma Des. (2004) 17:765–783.
   Web of Science ®Google Scholar
• CAPPELLI A, GIULIANI G, PERICOT GM et al: A non-peptide NK1 receptor agonist showing subpicomolar affinity. J. Med. Chem. (2004) 47:1315–1318.
   PubMedGoogle Scholar
• ALBERT JS, OHNMACHT C, BERNSTEIN PR et al: Design and optimization of cyclized NK1 antagonists with controlled atropisomeric properties. 7etr. (2004) 60:4337–4347.
   Google Scholar
• ALBERT JS, AHARONY D, ANDISIK D et al: Design, synthesis, and SAR of tachykinin antagonists: modulation of balance in NK1/NK2 receptor antagonist activity. J. Med. Chem. (2002) 45:3972–3983.
   PubMed Web of Science ®Google Scholar
• BENSAID M, FAUCHEUX BA, HIRSCH E et al: Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci. Lett. (2001) 303:25–28.
   PubMed Web of Science ®Google Scholar
• SAFFROY M, TORRENS Y, GLOWINSKI J, BEAUJOUAN JC: Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience (2003) 116:761–773.
   PubMed Web of Science ®Google Scholar
• STEINBERG R, ALONSO R, GRIEBEL G et al: Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function." Pharmacol Exp. Ther. (2001) 299:449–458.
   PubMed Web of Science ®Google Scholar
• DES VIGNES C, ROUQUIER L, SOUILHAC J et al.: Control by tachykinin NK2 receptors of CRF1 receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea-pig. Neuropeptides (2003) 37:89–97.
   PubMedGoogle Scholar
• SANOFI-SYNTHELABO: Press release. 16 February (2004).
   Google Scholar
• MELTZER HY, ARVANITIS L, BAUER D, REIN W: Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am,/ Psychiatry (2004) 161:975–984.
   PubMed Web of Science ®Google Scholar
• •First clinical trial results for NK3 in psychosis.
   Google Scholar
• EMONDS-ALT X, PRO IETTO V, STEINBERG R et al.: Biochemical and pharmacological activities of SSR-146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can. Phy. PharmacoL (2002) 80:482–488.
   PubMed Web of Science ®Google Scholar
• GLAXOSMITHKLINE: Analyst presentation, London. 3 December (2003).
   Google Scholar
• RYCKMANS T, BERTON 0, GRIMEE R et al.: Dual NK1 antagonists-serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives. Bioorg. Med. Chem. Lett. (2002) 12:3195–3198.
   Google Scholar
• GENICOT C, CHRISTOPHE B, COLLART P et al.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:437–442.
   PubMedGoogle Scholar
• GUIARD BP, PRZYBYLSKI C, GUILLOUXJ-P et al.: Blockade of substance P (neurokinin-1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. Neurochem. (2004) 89:54–63.
   PubMed Web of Science ®Google Scholar
• HENSLEY S, LANDERS P Wall Street Journal24 Feb. (2004).
   Google Scholar